id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-D-1167-0027,FDA,FDA-2014-D-1167,Controlled Correspondence Related to Generic Drug Development; Guidance for Industry; Availability,Notice,Notice of Availability,2024-03-18T04:00:00Z,2024,3,,,2024-03-20T12:35:59Z,2024-05687,0,0,09000064864808b5
FDA-2014-D-1167-0028,FDA,FDA-2014-D-1167,Controlled Correspondence Related to Generic Drug Development; Guidance for Industry,Other,Guidance,2024-03-18T04:00:00Z,2024,3,2024-03-18T04:00:00Z,,2025-04-17T16:24:57Z,,1,0,0900006486481276
FDA-2014-D-1167-0024,FDA,FDA-2014-D-1167,Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2022-12-22T05:00:00Z,2022,12,,,2022-12-22T13:50:27Z,2022-27827,0,0,090000648554d546
FDA-2014-D-1167-0025,FDA,FDA-2014-D-1167,Controlled Correspondence Related to Generic Drug Development; Guidance for Industry; Draft Guidance,Other,Guidance,2022-12-22T05:00:00Z,2022,12,2022-12-22T05:00:00Z,2023-02-22T04:59:59Z,2024-03-18T13:33:56Z,,0,0,090000648554cff7
FDA-2014-D-1167-0022,FDA,FDA-2014-D-1167,Controlled Correspondence Related to Generic Drug Development; Guidance for Industry,Other,Guidance,2020-12-17T05:00:00Z,2020,12,2020-12-17T05:00:00Z,,2022-12-22T13:59:06Z,,0,0,09000064849a5cce
FDA-2014-D-1167-0021,FDA,FDA-2014-D-1167,Controlled Correspondence Related to Generic Drug Development; Guidance for Industry; Availability,Notice,Notice of Availability,2020-12-17T05:00:00Z,2020,12,2020-12-17T05:00:00Z,,2020-12-17T19:19:44Z,2020-27810,0,0,09000064849a4518
FDA-2014-D-1167-0017,FDA,FDA-2014-D-1167,Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability; Correction,Notice,Correction,2017-11-17T05:00:00Z,2017,11,2017-11-17T05:00:00Z,,2017-11-17T20:10:11Z,2017-24948,0,0,0900006482c8a43d
FDA-2014-D-1167-0016,FDA,FDA-2014-D-1167,Draft Guidance for Industry on Controlled Correspondence Related to Generic Drug Development,Other,Guidance,2017-11-03T04:00:00Z,2017,11,2017-11-03T04:00:00Z,,2022-12-22T13:58:49Z,,0,0,0900006482c3ee67
FDA-2014-D-1167-0015,FDA,FDA-2014-D-1167,"Controlled Correspondence Related to Generic Drug Development; 
Draft Guidance for Industry; Availability",Notice,Notice of Availability,2017-11-03T04:00:00Z,2017,11,2017-11-03T04:00:00Z,2018-01-03T04:59:59Z,2018-01-03T02:01:35Z,2017-23947,0,0,0900006482c3e633
FDA-2014-D-1167-0014,FDA,FDA-2014-D-1167,"Agency Information Collection Activities; Announcement of Office 
of Management and Budget Approval; Guidance for Industry on Controlled Correspondence Related to Generic Drug Development",Notice,Notice of Approval,2015-10-30T04:00:00Z,2015,10,2015-10-30T04:00:00Z,,2019-06-18T16:45:55Z,2015-27741,0,0,0900006481cfcaa7
FDA-2014-D-1167-0012,FDA,FDA-2014-D-1167,Controlled Correspondence Related to Generic Drug Development; Guidance for Industry; Availability,Notice,Notice of Availability,2015-09-29T04:00:00Z,2015,9,2015-09-29T04:00:00Z,,2015-09-29T14:14:27Z,2015-24621,0,0,0900006481ca0e1f
FDA-2014-D-1167-0013,FDA,FDA-2014-D-1167,"Controlled Correspondence Related to Generic Drug Development
Guidance for Industry",Other,Guidance,2015-09-29T04:00:00Z,2015,9,2015-09-29T04:00:00Z,,2019-06-18T16:45:38Z,,0,0,0900006481ca1ef1
FDA-2014-D-1167-0003,FDA,FDA-2014-D-1167,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry on Controlled Correspondence Related to Generic Drug Development,Notice,30 Day Proposed Information Collection,2015-07-02T04:00:00Z,2015,7,2015-07-02T04:00:00Z,2015-08-04T03:59:59Z,2015-08-04T01:30:57Z,2015-16358,0,0,0900006481b670a4
FDA-2014-D-1167-0002,FDA,FDA-2014-D-1167,Draft Guidance for Industry on Controlled Correspondence Related to Generic Drug Development,Other,Guidance,2014-08-27T04:00:00Z,2014,8,2014-08-27T04:00:00Z,,2019-06-18T16:45:19Z,,0,0,09000064818483c9
FDA-2014-D-1167-0001,FDA,FDA-2014-D-1167,"Draft Guidance for Industry on Controlled Correspondence Related to
Generic Drug Development; Availability",Notice,Notice of Availability,2014-08-27T04:00:00Z,2014,8,2014-08-27T04:00:00Z,2014-10-28T03:59:59Z,2015-09-12T01:31:10Z,2014-20359,0,0,0900006481847bfd